

| 规格 | 价格 | 会员价 | 库存 | 数量 | |||
|---|---|---|---|---|---|---|---|
| {[ item.pr_size ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]} | 现货 | 1周 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解

| 产品名称 | 20S proteasome ↓ ↑ | Proteasome ↓ ↑ | 其他靶点 | 纯度 | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ixazomib |
++++
20S proteasome, Ki: 0.93 nM 20S proteasome, IC50: 3.4 nM |
99%+ | |||||||||||||||||
| Delanzomib |
+++
Chymotrypsin-like proteasome, IC50: 3.8 nM |
98% | |||||||||||||||||
| Celastrol |
+
20S proteasome, IC50: 2.5 μM |
98% | |||||||||||||||||
| MLN9708 |
+++
20S proteasome, Ki: 0.93 nM 20S proteasome, IC50: 3.4 nM |
99% | |||||||||||||||||
| Bortezomib |
++++
20S proteasome, Ki: 0.6 nM |
98% | |||||||||||||||||
| Oprozomib |
++
20S proteasome LMP7, IC50: 82 nM 20S proteasome β5, IC50: 36 nM |
99%+ | |||||||||||||||||
| Epoxomicin | ✔ | 95% | |||||||||||||||||
| PI-1840 |
++
Chymotrypsin-like proteasome, IC50: 27 nM |
98% | |||||||||||||||||
| VR23 |
+++
Trypsin-like proteasomes, IC50: 1 nM Chymotrypsin-like proteasomes, IC50: 3 μM |
99% | |||||||||||||||||
| Carfilzomib |
++
Proteasome, IC50: 5 nM |
98% | |||||||||||||||||
| (R)-MG-132 |
+
Proteasome, IC50: 100 nM |
98% (NMR) | |||||||||||||||||
| 1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。 | |||||||||||||||||||
| 靶点 |
|
| 描述 | (R)-MG132 can act as an inhibitor of proteasome and be used in ubiquitination assay. |
| Concentration | Treated Time | Description | References | |
| mouse brain synaptosomes | 10 µM | 30 min | To investigate the effects of proteasome inhibition on presynaptic architecture and function, results showed that MG132 treatment significantly reversed the structural defects in RIM1α KO synapses and restored release probability to WT levels. | J Cell Biol. 2013 May 27;201(5):725-40. |
| HEI-193 schwannoma cells | 2.5 μM | 24, 48, 72 h | To evaluate the inhibitory effect of MG-132 combined with Nutlin-3 on the proliferation of schwannoma cells. Results showed that MG-132 enhanced the inhibitory effect of Nutlin-3 on cell proliferation. | EBioMedicine. 2018 Oct;36:252-265. |
| RT4-D6P2T schwannoma cells | 2.5 μM | 24, 48, 72 h | To evaluate the inhibitory effect of MG-132 combined with Nutlin-3 on the proliferation of schwannoma cells. Results showed that MG-132 enhanced the inhibitory effect of Nutlin-3 on cell proliferation and narrowed the sensitivity differences between cells with different merlin expression status. | EBioMedicine. 2018 Oct;36:252-265. |
| Naïve CD4+ T cells | 10 µM | 2 h | Promote CD69+ iTregs differentiation | Theranostics. 2023 Mar 21;13(6):1892-1905. |
| RVSMCs | 10 μM | 6 days | Treatment with MG132 or lactacystin halved Pi-induced calcium deposition, demonstrating proteasome inhibition alleviates vascular calcification | Nat Commun. 2016 Feb 1;7:10492. |
| A10 cells (RVSMC line) | 10 μM | 4 h | MG132 treatment enhanced HDAC1 ubiquitination under Pi stimulation, confirming HDAC1 degradation via the proteasomal pathway | Nat Commun. 2016 Feb 1;7:10492. |
| rat vascular smooth muscle cells (RVSMCs) | 10 μM | 4 h | MG132 markedly attenuated Pi-induced HDAC1 reduction, indicating proteasomal inhibition prevents HDAC1 degradation | Nat Commun. 2016 Feb 1;7:10492. |
| Plasmodium falciparum 3D7 parasite-infected red blood cells | 100 nM | 72 h | Inhibition of 26S proteasome activity significantly inhibited α-spectrin degradation and parasite proliferation | mBio. 2024 Apr 10;15(4):e0351023. |
| Administration | Dosage | Frequency | Description | References | ||
| BALB/c nude mice | RT4-D6P2T and HEI-193 schwannoma xenograft models | Intraperitoneal injection | 5 mg/kg | Once daily for 14 days | To evaluate the inhibitory effect of MG-132 combined with Nutlin-3 on the growth of schwannoma xenografts. Results showed that the combined treatment significantly inhibited tumor growth and induced apoptosis of tumor cells. | EBioMedicine. 2018 Oct;36:252-265. |
| Mice | DSS-induced colitis model | Intraperitoneal injection | 15 μM/kg | 9 days | Promote CD69+ Tregs differentiation but fail to effectively alleviate colitis | Theranostics. 2023 Mar 21;13(6):1892-1905. |
| Mice | VD3-induced vascular calcification model | Intraperitoneal injection | 2.5 mg/kg | Daily administration for 9 days | MG132 significantly reduced VD3-induced aortic calcium deposition and prevented HDAC1 downregulation | Nat Commun. 2016 Feb 1;7:10492. |
| Mouse | P23H mice | Intraperitoneal injection | 5 mg/kg | Single injection | To enhance the detection of ubiquitinated proteins | Cell Death Dis. 2019 Jul 18;10(8):547 |
| C57BL/6 mice | Plasmodium berghei ANKA infection model | Intraperitoneal injection | 1.5 mg/kg | Once daily for 9 days | Inhibition of 26S proteasome activity significantly reduced parasitemia | mBio. 2024 Apr 10;15(4):e0351023. |
| Mice | Vitamin D receptor knockout mice | Intraperitoneal injection | 2.5 mg/kg | Once daily for 2 days | To assess protein ubiquitination levels, results showed higher total ubiquitination and K48-linked ubiquitination in skeletal muscles of vdr /C0//C0 mice. | J Cachexia Sarcopenia Muscle. 2022 Feb;13(1):467-480 |
| Mice | Healthy mice | Intraperitoneal injection | 10 μg/kg | Single injection, samples collected after 24 hours | MG-132, as a proteasome inhibitor, was used to study the effect of agmatine on β-catenin stability. Results showed that agmatine increased β-catenin stability by suppressing Rnf128-mediated ubiquitination degradation. | Gut Microbes. 2024 Jan-Dec;16(1):2348441 |
| Mice | Wildtype mice | Intraperitoneal injection | 50µg/g | Single injection, analyzed after 3 hours | MG132 significantly increased VEGF receptor levels in type H vessel columns | Nat Cell Biol. 2017 Mar;19(3):189-201 |
| 计算器 | ||||
| 存储液制备 | ![]() |
1mg | 5mg | 10mg |
|
1 mM 5 mM 10 mM |
2.10mL 0.42mL 0.21mL |
10.51mL 2.10mL 1.05mL |
21.03mL 4.21mL 2.10mL |
|
| CAS号 | 1211877-36-9 |
| 分子式 | C26H41N3O5 |
| 分子量 | 475.62 |
| SMILES Code | [C@H](NC([C@@H](NC(OCC1=CC=CC=C1)=O)CC(C)C)=O)(C(N[C@@H](CC(C)C)C=O)=O)CC(C)C |
| MDL No. | MFCD28580122 |
| 别名 | (S,R,S)-(-)-MG-132; Z-Leu-D-Leu-Leu-al; MG132 |
| 运输 | 蓝冰 |
| 存储条件 |
In solvent -20°C: 3-6个月 -80°C: 12个月 Pure form Inert atmosphere, store in freezer, under -20°C |
| 溶解方案 |
DMSO: 105 mg/mL(220.76 mM),配合低频超声助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO 以下溶解方案都请先按照体外实验的方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议现用现配,当天使用; 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶
|
沪公网安备 31011702889066号
沪ICP备2024050318号-1